Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

10. Juni 2025 17:55 ET | Quelle: Philogen S.p.A.

Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royalties

Philochem Licensing of OncoACP3 to RayzeBio for potential value of up to $1.35bn plus royalties
20. Februar 2024 01:30 ET | Quelle: Philogen S.p.A.

Philogen provides update on pre-planned interim analysis of the Phase III FIBROSARC trial investigating Onfekafusp alfa (L19TNF) in patients with first-line advanced or metastatic Soft Tissue Sarcoma

Interim analysis of the Phase III FIBROSARC trial investigating L19TNF in patients with first-line Soft Tissue Sarcoma
05. Dezember 2023 02:30 ET | Quelle: Philogen S.p.A.

Philogen S.p.A. announces receipt of the Good Manufacturing Practice Certificate for its new Production facility in Rosia (Siena, Italy) by Competent Authorities

Philogen new production facility in Rosia has received the GMP certificate by Competent Authorities
04. Dezember 2023 03:00 ET | Quelle: Philogen S.p.A.; Blue Earth Diagnostics

Philochem and Blue Earth Diagnostics Announce First Three Patients Imaged in Phase 1 Clinical Trial of 68Ga-OncoFAP (68Ga-OncoFAP-DOTAGA) for Diagnostic Imaging in Solid Tumors

Philochem (Philogen) and Blue Earth Diagnostic (Bracco) announce the three first patients in the Phase I trial have been imaged with 68Ga-OncoFAP
16. Oktober 2023 08:21 ET | Quelle: Philogen S.p.A.

Nidlegy™ Phase III PIVOTAL trial meets the study’s primary objective demonstrating statistically significant and clinically meaningful improvement in Recurrence-Free Survival for patients with locally advanced fully resectable melanoma

Nidlegy™ Phase III PIVOTAL trial meets the study’s primary objective for patients with locally advanced fully resectable melanoma